JPRN-UMIN000001966已完成未知
Clinical study of a combined use of EGFR-TKI and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer. - Clinical study of a combined use of EGFR-TKI and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.
Juntendo University, School of Medicine0 个研究点目标入组 10 人开始时间: 2009年5月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who have: -Previous history of hypersensitivity to EGFR-TKI -Uncontrolled infections -Active autoimmune diseases -Serious cardiac disease -Continuous systemic administration of steroids. -Other cancer who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study.
研究者
相似试验
招募中
2 期
Phase II study of EGFR-TKI in elderly patients with lung cancer harboring EGFR gene mutation in liquid biopsyon-small cell lung cancerJPRN-UMIN000025624Respiratory Center. Asahikawa Medical University Hospital26
已完成
2 期
Multicenter phase II trial of continuous EGFR-TKIs for elderly patients with EGFR sensitive mutation who failed the first EGFR-TKIs treatment for advanced non-small cell lung cancer.JPRN-UMIN000008027ung Oncology Group in Kyushu, Japan (LOGIK)70
已完成
不适用
Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790MJPRN-UMIN000015568Okayama University Hospital12
已完成
不适用
The Effect of EGFR TKI Treatment Based on Liquid Biopsy Panel Screening in Patients with Non-Small Cell Lung CancerKCT0003324The Catholic University of Korea, Seoul St. Mary's Hospital198
已完成
不适用
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase in sensitizing EGFR mutation positive Non-Squamous Cell carcinoma patientsKCT0003243Koera University Guro Hospital69